中国人兽共患病学报2024，Vol.40Issue(6)：578-582,589,6.DOI:10.3969/j.issn.1002-2694.2024.00.084
抗拉沙病毒药物的研究进展
Recent progress in the development of inhibitors of the Lassa virus
摘要
Abstract
Lassa virus(LASV),a member of Arenaviridae family,is the cause of severe acute hemorrhagic fever,known as Lassa fever,which has an overall fatality rate of 1％,but up to 15％in hospitalized patients.LASV is mainly endemic in West Africa.At present,there is no approved drug or vaccine for LASV,and treatment is limited to ribavirin in the early dis-ease stage.Although some drugs have entered the clinical stage,most have been studied in cellular and animal models.Accord-ing to the Centers for Disease Control and Prevention,LASV is a Class A pathogen due to a high mortality rate and limited treatment options.The World Health Organization has identified Lassa fever as a top priority for research and development.This article reviews recent progress in the development of LASV inhibitors.关键词
拉沙病毒/抑制剂/包膜糖蛋白复合物/病毒靶标Key words
Lassa virus/inhibitor/envelope glycoprotein complex/virus targe分类
医药卫生引用本文复制引用
刘贞麟,李志豪,刘奇,王聪..抗拉沙病毒药物的研究进展[J].中国人兽共患病学报,2024,40(6):578-582,589,6.基金项目
Supported by the National Natural Science Foundation of China(No.82360727),and the Joint Special Project of Local Univer-sities in Yunnan Province(No.202101BA070001-114) 国家自然科学基金项目(No.82360727)和云南省地方高校联合专项-面上项目(No.202101BA070001-114)联合资助 （No.82360727）
